Septic Arthritis
Clinical Snapshot
Septic arthritis is a bacterial infection within a joint space — a true orthopedic and medical emergency, not merely another cause of a painful joint. Once bacteria establish themselves in synovial fluid, the combination of bacterial toxins, host inflammatory cytokines, and neutrophil-derived proteolytic enzymes can destroy articular cartilage within 24 to 48 hours, and that destruction is irreversible — cartilage has essentially no capacity to regenerate.[1][2] Every hour spent debating the diagnosis is an hour the joint is actively being destroyed, which is why this chapter is organized around a single, non-negotiable safety message: any acutely painful, swollen, warm joint with restricted range of motion must be treated as septic arthritis until proven otherwise, with urgent joint aspiration — not a fever curve, not a white cell count, not a wait to see how the patient trends — as the diagnostic step that actually rules the condition in or out.[3]
A normal or low-grade temperature and a normal peripheral white cell count do NOT exclude septic arthritis. Fever is present in only about 40-60% of confirmed cases and is itself a nonspecific finding; serum white cell count, ESR, and CRP each have weak individual discriminatory power (positive likelihood ratios of only about 1.3 to 1.6).[1][3] This is one of the most commonly missed points in the initial assessment of a hot joint, and missing it costs the patient irreplaceable cartilage.
This chapter covers the classic causative organisms by age and risk group, empiric antibiotic selection pending culture results, the essential, non-optional role of urgent surgical joint drainage alongside (never instead of) antibiotics, prosthetic joint infection as a distinct and more complex management scenario, and the important, easily missed diagnostic nuance that gout and pseudogout can look identical to septic arthritis at the bedside and can even coexist with it in the same joint.
Recognize the Condition
Pathophysiology and routes of infection
The synovial membrane lining a joint has a rich blood supply and, unlike most other tissues, no limiting basement membrane separating it from the vascular space — a combination that makes the joint an unusually easy target for hematogenous seeding during transient or sustained bacteremia, the dominant route by which most native joints become infected.[2][1] Once organisms are established in the synovium, bacterial proteases and toxins combine with the host's own neutrophil-driven inflammatory response to degrade cartilage matrix — a process that begins within hours, not days.[1] Two other routes matter clinically: direct inoculation, from a penetrating injury, an intra-articular injection, arthroscopy, or open joint surgery; and contiguous spread from an adjacent focus of osteomyelitis, particularly in young children, whose metaphyseal blood vessels cross the growth plate into the joint space.
Who has which organism — and why it changes empiric coverage
Adults overall
Staphylococcus aureus is the single most common cause of native-joint septic arthritis in adults, and methicillin-resistant strains (MRSA) are common enough in most communities that empiric coverage should assume MRSA is possible until a Gram stain or culture says otherwise.[1][2] Streptococcal species are the next most frequent cause.
Sexually active young adults
Neisseria gonorrhoeae is a leading cause of acute, nontraumatic monoarthritis in this population and needs to be actively considered as its own diagnostic category, not simply folded into "septic arthritis" generically — its presentation, culture yield, and treatment all differ meaningfully from staphylococcal disease (see below, and Choose Initial Treatment).[1]
Neonates and young infants
Staphylococcus aureus remains common, but group B streptococcus and gram-negative enteric organisms (e.g., E. coli) are also important in this age group, and critically unwell neonates can be infected with Candida species.
Children under about 2-3 years
Kingella kingae is now recognized as a leading cause of septic arthritis in this specific age band — a fastidious, slow-growing gram-negative organism that is easily missed on standard culture and better detected with nucleic acid amplification/PCR testing of synovial fluid where available; S. aureus remains common as well.[4]
Older adults, and anyone with a prosthetic joint, indwelling catheter, or significant comorbidity
Gram-negative organisms (e.g., E. coli, other Enterobacterales) become proportionally more common, and coagulase-negative staphylococci and Cutibacterium acnes are important specifically in prosthetic joint infection, where they can be true pathogens despite looking like a "contaminant" on a single culture (see Special Populations).
People who inject drugs
Pseudomonas aeruginosa and other gram-negative organisms are disproportionately represented, and infection can involve atypical, harder-to-examine sites — the sternoclavicular, sacroiliac, and pubic symphysis joints — that are easy to under-recognize as joint infections in the first place.
Sickle cell disease
Salmonella species are a classic and disproportionately represented cause in this population, alongside S. aureus — and a genuinely important, easily missed trap is attributing new joint or bone pain in a patient with sickle cell disease automatically to a vaso-occlusive crisis without actively considering infection (see Special Populations).
Clinical presentation
The classic presentation is acute-onset monoarticular pain, swelling, warmth, and erythema with markedly restricted active and passive range of motion — the restriction of passive range of motion in particular is a genuinely useful discriminating feature, since periarticular processes such as bursitis or cellulitis typically still allow passive movement of the joint itself. The knee is the single most commonly affected joint, followed by the hip (especially in children), shoulder, wrist, and ankle; roughly 10-20% of cases involve more than one joint, and polyarticular involvement is associated with higher morbidity and mortality and should raise suspicion for bacteremia, endocarditis, or a disseminated process.[2]
The distinct presentation of disseminated gonococcal infection
Disseminated gonococcal infection (DGI) typically begins with a prodrome of migratory polyarthralgias and tenosynovitis — often affecting the wrists, fingers, knees, and ankles in a fleeting, moving pattern — before evolving along one of two overlapping patterns: a purulent, often monoarticular or oligoarticular arthritis that looks like classic septic arthritis, or the "arthritis-dermatitis" syndrome — the triad of tenosynovitis, dermatitis (a small number of painless or minimally tender vesiculopustular or hemorrhagic lesions, typically on the distal extremities near joints), and polyarthralgia, without frank purulent arthritis.[1][5] This distinction genuinely matters at the bedside: in the arthritis-dermatitis pattern, joint fluid culture is frequently negative even when the diagnosis is correct, and blood culture, cervical/urethral/pharyngeal/rectal nucleic acid amplification testing (NAAT), and culture of a skin lesion are all more likely to be revealing than the joint aspirate alone — a genuinely high-yield point, since a negative joint fluid culture is sometimes wrongly taken as evidence against the diagnosis.[1] Risk factors specific to dissemination (as opposed to acquiring uncomplicated gonorrhea in the first place) include female sex, menstruation, pregnancy, and terminal complement pathway deficiency, including iatrogenic complement inhibition with an agent such as eculizumab.[6]
Risk Factors
- Bacteremia from any source (skin/soft-tissue infection, an IV catheter, a dental procedure, endocarditis) — the dominant route of infection for most native joints.[2]
- Pre-existing joint disease, especially rheumatoid arthritis or another inflammatory arthropathy, or a joint already damaged by osteoarthritis or prior injury — an already-inflamed, hyperemic joint is more susceptible to hematogenous seeding, and pre-existing joint disease also makes a new infection harder to recognize against a background of chronic pain and swelling.
- A prosthetic joint — a distinct risk category with its own diagnostic thresholds and management approach (see Special Populations).
- Age over about 80, or age under 2-3 years.
- Diabetes mellitus, chronic corticosteroid use, or another cause of immunosuppression (HIV, malignancy, chemotherapy, biologic/immunosuppressive therapy).
- Chronic kidney disease, particularly on hemodialysis, and cirrhosis.
- Injection drug use.
- Recent intra-articular corticosteroid injection, arthroscopy, or joint surgery.
- A skin or soft tissue infection, ulcer, or breach overlying or near a joint.
- Sexual risk factors for gonococcal arthritis: young age, multiple partners, unprotected intercourse; menstruation, pregnancy, and terminal complement deficiency specifically raise the risk of dissemination once infection occurs, rather than the risk of acquiring gonorrhea itself.[6]
- Sickle cell disease.
- Malignancy.
Red Flags & Refer
Treat any acutely hot, swollen, painful joint with restricted range of motion as a medical/orthopedic emergency until infection is excluded — this is true regardless of temperature, white cell count, or how well the patient otherwise looks. Arrange same-day, not routine, orthopedic (and, where available, infectious diseases) involvement, and do not let imaging delay urgent joint aspiration when clinical suspicion is genuinely high.[1][3]
- Any acute monoarticular or oligoarticular joint pain and swelling with restricted range of motion, especially with fever, chills, or another sign of systemic infection.
- Any new or worsening joint pain, swelling, wound drainage, or systemic symptoms in a patient with a prosthetic joint — this needs urgent orthopedic assessment using prosthetic-joint-specific diagnostic thresholds, not the native-joint pathway (see Special Populations).
- Hip pain or refusal to bear weight in a child — the hip is a deep joint that is difficult to examine and follow serially, carries the highest risk of avascular necrosis of the femoral head if infection is missed or delayed, and should prompt urgent orthopedic involvement rather than a period of outpatient observation.
- Polyarticular involvement, or any sign of hemodynamic instability, sepsis, or bacteremia — raises the stakes and the need for a broader source-control workup (e.g., for endocarditis) alongside joint-specific management.
- Any immunocompromised patient (diabetes, corticosteroid use, HIV, malignancy, dialysis, cirrhosis) with new joint symptoms — presentation can be blunted and atypical, so the threshold to aspirate should be lower, not higher, in this group.
- New joint or bone pain in a patient with sickle cell disease — do not assume this is simply a vaso-occlusive crisis without actively considering septic arthritis or osteomyelitis, particularly if the pain pattern, joint findings, or fever are not typical for the patient's usual crises.
- Suspected disseminated gonococcal infection — hospitalize for initial management and involve infectious diseases; this reflects the systemic nature of the process, not just the joint findings.[6]
Assessment & Diagnosis
History and examination
Characterize onset (acute versus gradual), the number of joints involved, and screen specifically for the risk factors and red flags above: recent bacteremia or skin infection, a prosthetic joint, immunosuppression, injection drug use, and sexual history/risk factors relevant to gonococcal disease. On examination, assess for warmth, erythema, effusion, and — the most discriminating single physical finding — marked restriction of both active and passive range of motion, since passive motion is often preserved in periarticular processes such as bursitis, cellulitis, or tendinopathy.
Laboratory testing
Obtain a complete blood count, ESR, and CRP, but interpret them cautiously: each has only weak individual discriminatory power (positive likelihood ratios of roughly 1.3-1.6 for an elevated serum white cell count, ESR, or CRP), and a normal result does not meaningfully lower the probability of septic arthritis once clinical suspicion is present.[3] Obtain two sets of blood cultures before starting antibiotics whenever possible — roughly half of adult, non-gonococcal cases have positive blood cultures, and a positive result both supports the diagnosis and can identify the organism when joint fluid culture is unrevealing.[2][1]
Arthrocentesis — the diagnostic cornerstone
Joint aspiration is the single most important diagnostic step, and should be performed before the first dose of antibiotics whenever feasible without meaningfully delaying treatment of a septic or hemodynamically unstable patient — prior antibiotic exposure reduces synovial fluid culture yield.[1] Send synovial fluid for cell count and differential; Gram stain; aerobic and anaerobic culture (with NAAT for N. gonorrhoeae/C. trachomatis where gonococcal disease is a possibility); and crystal analysis under polarized microscopy — every time, regardless of how confidently the clinical picture "looks like" gout or pseudogout (see the crystal-arthropathy discussion below).
| Synovial fluid finding | Interpretation |
|---|---|
| Grossly purulent or turbid appearance | Supports septic arthritis, but a less purulent appearance does not exclude it, particularly in gonococcal or early infection |
| WBC count >100,000 cells/mm³ | Highly specific for septic arthritis (93-100%) but poorly sensitive (only 13-40%) — a lower count does not rule infection out[3] |
| WBC count roughly 50,000-100,000 cells/mm³ | Substantially raises the probability of septic arthritis; culture-directed decision-making is still required |
| WBC count roughly 25,000-50,000 cells/mm³ | Modestly raises probability; insufficient alone to rule in or out |
| ≥90% polymorphonuclear cells | Supportive, but has only moderate discriminatory accuracy in either direction (sensitivity 57-92%, specificity 68-83%)[3] |
| A lower-than-expected WBC count | Can occur in early infection, peripheral leukopenia, a prosthetic joint, and — importantly — disseminated gonococcal infection; a modest count does not exclude any of these[1] |
| Positive crystal analysis (monosodium urate or calcium pyrophosphate) | Supports gout or pseudogout, but does not exclude coexisting infection — send Gram stain and culture regardless[7] |
Gram stain identifies the organism in roughly half of confirmed staphylococcal/streptococcal cases, but sensitivity is considerably lower for gram-negative organisms and for gonococcus specifically — a negative Gram stain never rules out septic arthritis on its own.[1][2]
Imaging
Plain radiographs are a reasonable baseline (they can show a joint effusion, pre-existing joint damage, or an adjacent bony abnormality) but are usually normal early in the disease course and should never delay arthrocentesis. Point-of-care ultrasound is useful to confirm an effusion and can guide aspiration of a joint that is difficult to access clinically, notably the hip. MRI is the most sensitive imaging study for early joint infection and for detecting adjacent osteomyelitis, and is particularly useful for the pediatric hip and for suspected prosthetic joint infection — but obtaining it should never come before, or meaningfully delay, urgent aspiration and orthopedic involvement when clinical suspicion is high.
A pediatric-specific tool: the Kocher criteria for the irritable hip
In a child with an acutely irritable hip, the Kocher clinical prediction algorithm combines four independent predictors — inability to bear weight, ESR ≥40 mm/hr, fever, and serum WBC >12,000/µL — to estimate the probability of septic arthritis versus the far more common and benign transient synovitis.[8] A subsequent validation cohort found the rule performs less well prospectively than at its original derivation, and predicted probabilities should be interpreted with that in mind:
| Number of Kocher criteria present | Predicted probability of septic arthritis (validation cohort) |
|---|---|
| 0 | ~2% |
| 1 | ~9.5% |
| 2 | ~35% |
| 3 | ~72.8% |
| 4 | ~93% |
Use this table as one input into clinical judgment, not as a stand-alone decision rule — it was derived primarily from a cohort dominated by S. aureus infection, and it performs less reliably in children under about 4 years old, where Kingella kingae is proportionally more important and can present more subtly than the classic picture the rule was built around.[8][4] A low predicted probability should lower, not eliminate, clinical concern in a child who otherwise looks unwell.
Treatment Targets
- Confirm the diagnosis urgently with arthrocentesis, without letting the workup delay definitive treatment once infection is strongly suspected.
- Achieve source control with urgent surgical drainage of the infected joint — this is not optional, and antibiotics alone do not substitute for it.[1]
- Start empiric intravenous antibiotics covering the likely organism(s) by age and risk factors immediately after cultures are obtained, without waiting for results.
- De-escalate to targeted, narrow-spectrum therapy once an organism and susceptibilities are known.
- Preserve joint function and prevent irreversible cartilage destruction, adjacent osteomyelitis, and systemic sepsis.
- Recognize and manage prosthetic joint infection as its own, distinct problem — different diagnostic thresholds, and a surgical strategy decision (retain vs. remove the prosthesis) that drives the entire treatment plan.
- Actively look for and, where present, treat coexisting crystal arthropathy — without ever letting a positive crystal result substitute for excluding infection.
- For gonococcal disease, treat the systemic/disseminated process, not just the joint, and complete the associated STI-management bundle: partner notification, empiric partner treatment, and screening for other STIs.
Choose Initial Treatment
Aspirate urgently, start empiric antibiotics without delay, and arrange surgical drainage — all three, not just one
Obtain synovial fluid (and blood) cultures before the first antibiotic dose whenever feasible without materially delaying care of an unstable patient.[1] Every confirmed or strongly suspected case arrange urgent orthopedic surgical consultation for joint drainage (arthrotomy or arthroscopic washout; the hip in particular is almost always managed surgically rather than by serial needle aspiration, given how poorly accessible and how consequential a missed hip infection is) — antibiotics alone are not adequate source control.[1][10] Typical adult, no specific gonococcal or pseudomonas risk vancomycin PLUS a third-generation cephalosporin (ceftriaxone), covering MRSA and the likely gram-negative organisms pending culture.[1] IV drug use, immunocompromise, or another pseudomonas risk factor substitute or add ceftazidime (or another antipseudomonal agent, e.g., piperacillin-tazobactam) for broader gram-negative coverage in place of ceftriaxone. Sexually active young adult with a presentation consistent with gonococcal arthritis or the arthritis-dermatitis syndrome ceftriaxone 1 g IM or IV every 24 hours; add doxycycline 100 mg PO twice daily for 7 days if chlamydial infection has not been excluded; hospitalize for initial management and involve infectious diseases.[6]
Neonates and young children
Neonates cefotaxime has historically been preferred over ceftriaxone in this age group because ceftriaxone can displace bilirubin from albumin, raising kernicterus risk in a hyperbilirubinemic neonate or one receiving calcium-containing IV fluids; where cefotaxime is unavailable, ceftriaxone can be considered case-by-case in a low-risk neonate without hyperbilirubinemia, but this should be a deliberate, informed substitution rather than a default one.[11] Pair with an antistaphylococcal agent (e.g., vancomycin if MRSA risk, or cloxacillin) based on local epidemiology and severity. Children under about 2-3 years cefazolin provides reliable coverage of both MSSA and Kingella kingae, the two dominant pathogens in this age group, and is the empiric agent used in current Canadian pediatric guidance; broaden to include MRSA coverage (e.g., add vancomycin or clindamycin, depending on local resistance patterns) if risk factors or a concerning Gram stain suggest it.[4]
De-escalation and duration
Once an organism and susceptibilities are available, narrow to targeted therapy — for example, cloxacillin or cefazolin for confirmed MSSA, continued vancomycin (or an alternative such as daptomycin or linezolid) for MRSA, and a susceptibility-directed agent for a gram-negative isolate. Total duration for native-joint, non-gonococcal septic arthritis has traditionally been about 3-4 weeks (longer, up to 6 weeks, for more severe S. aureus disease or a slow clinical response), but the evidence base has been shifting toward shorter courses when source control has genuinely been adequate: a randomized non-inferiority trial in non-immunocompromised adults found that 2 weeks of antibiotic therapy after thorough surgical drainage was non-inferior to 4 weeks (remission ~99% vs. 97%).[12] Individualize the actual duration to the organism, adequacy of source control, and clinical trajectory rather than applying one fixed number to every patient, and favour an early switch from intravenous to a highly bioavailable oral agent once the patient is clinically improving, afebrile, and able to tolerate oral intake — an approach with strong trial-level support in bone and joint infection generally (see the Prosthetic Joint Infection discussion under Special Populations).[13] For gonococcal arthritis/arthritis-dermatitis syndrome specifically, switch to an oral agent guided by susceptibility testing once there has been substantial clinical improvement for 24-48 hours, for a total treatment course of more than 7 days.[6]
A note on Canadian guidance for gonococcal disease
The Public Health Agency of Canada's Canadian Guidelines on Sexually Transmitted Infections identify disseminated gonococcal infection as a recognized complication of gonorrhea but do not publish their own dose-and-duration regimen for it — instead, PHAC directs that complicated gonococcal infections, including disseminated disease, be managed by or in consultation with an infectious diseases specialist or an experienced colleague, with hospitalization for initial management.[14] The CDC regimen above is the most detailed, currently in-use clinical guidance available and is presented here for that reason, to be applied in the context of local/current infectious diseases consultation.
Non-Pharmacologic Treatment
- Urgent surgical joint drainage (arthrotomy or arthroscopic washout) is the central non-pharmacologic intervention in this chapter — it is not an adjunct to antibiotics, it is co-equal source control, and delaying it while "seeing how the antibiotics do" is a recognized cause of preventable joint destruction.[1][10]
- Repeat aspiration or repeat surgical washout if the joint reaccumulates fluid or the clinical response is inadequate — a single washout is not always sufficient, particularly for the knee.
- Splinting/immobilization in the acute phase for comfort, followed by early, progressive mobilization and physiotherapy once the infection is controlled — prolonged immobilization risks stiffness and contracture, especially at the knee and hip.
- Adequate analgesia, including short-term opioid therapy where needed — the pain of an acutely septic joint, and of the surgical drainage itself, is often severe, and under-treating it is a real, avoidable source of patient distress.
- Source control beyond the joint itself when bacteremia is present: remove or exchange an infected indwelling catheter, and evaluate for endocarditis (e.g., with echocardiography) in S. aureus bacteremia or a patient with a prosthetic heart valve, since the joint may be one manifestation of a broader bloodstream infection.
- Partner notification, empiric partner treatment, and a full STI screening bundle (chlamydia, syphilis, HIV) for confirmed or strongly suspected gonococcal arthritis — treat and notify partners from the preceding 60 days, consistent with standard Canadian STI-management practice, and report confirmed gonococcal infection to local public health.[14]
- Multidisciplinary coordination (orthopedic surgery, infectious diseases, and, for a prosthetic joint, the original implanting surgeon where possible) for any prosthetic joint infection, since the surgical strategy decision drives everything else (see Special Populations).
Special Populations
Pediatrics
Apply the same non-negotiable safety principle as in adults: a normal temperature or normal white cell count does not exclude septic arthritis in a child. In a child with an acutely irritable hip, the Kocher criteria (see Assessment & Diagnosis) can help estimate probability, but should never substitute for urgent orthopedic involvement when clinical suspicion is high, and perform less reliably in children under about 4 years old, where Kingella kingae is proportionally more important.[8][4] Current Canadian pediatric guidance from the Canadian Paediatric Society recommends empiric cefazolin 100-150 mg/kg/day divided every 6-8 hours, covering the two dominant pediatric pathogens (MSSA and Kingella kingae); broaden coverage if the Gram stain, local epidemiology, or clinical severity suggests MRSA or another organism.[4] A meaningful, real shift in duration has occurred in recent years: a total antibiotic duration of 3-4 weeks (transitioning to oral therapy once the child is clinically well and tolerating oral intake) is now typical for most uncomplicated cases with a good response — down from a previously standard 6 weeks — while hip septic arthritis specifically is still generally treated for a longer 4-6 weeks, given its higher stakes and historically higher complication rate.[4] Distinguish septic arthritis from the far more common and benign transient synovitis using the clinical picture as a whole (transient synovitis is associated with a lower-grade fever, gradual improvement over days, and a CRP typically under 20 mg/L) rather than any single test.[4]
Prosthetic joint infection
Infection involving a prosthetic joint is a genuinely distinct clinical problem, not simply "septic arthritis in someone who happens to have a joint replacement" — the diagnostic thresholds are different, the causative organisms skew toward lower-virulence skin flora that would be dismissed as contaminants in a native joint, and the treatment decision is fundamentally a surgical one about whether the prosthesis itself can be saved.
Diagnosis: different thresholds, and a sinus tract is diagnostic on its own
A sinus tract communicating with the joint or visible hardware is diagnostic of prosthetic joint infection by itself, without further testing.[15] Otherwise, synovial fluid WBC thresholds are considerably lower than in a native joint and depend on timing since implantation: a widely used, evidence-based definition uses roughly 3,000 cells/µL with more than 80% neutrophils as the threshold for chronic infection (generally more than about 90 days after implantation), compared with a substantially higher threshold, on the order of 10,000 cells/µL, in the acute postoperative period, when the normal inflammatory response to surgery itself elevates synovial cell counts.[16] Applying the native-joint threshold (tens of thousands of cells/µL) to a prosthetic joint will miss real infections. Obtain ESR and CRP as adjunctive, not stand-alone, tests; synovial fluid aspiration for cell count, differential, and culture — ideally with a meaningful antibiotic-free window beforehand if the patient's condition allows it, to maximize culture yield; and, at the time of surgery, multiple (at least three, ideally five to six) intraoperative tissue cultures, since a single positive culture in this setting is genuinely harder to interpret than in a native joint and can reflect contamination rather than true infection.[15]
Surgical strategy — the decision that drives everything else
Debridement, antibiotics, and implant retention (DAIR) is a reasonable strategy specifically for a well-fixed prosthesis with no sinus tract, presenting within roughly 30 days of implantation or within about 3 weeks of symptom onset.[15] Outside that window — a loose or poorly fixed prosthesis, a sinus tract, a late/chronic presentation, or a difficult-to-treat organism — prosthesis removal, as either a one-stage or, more commonly in North American practice, a two-stage exchange (removal, an antibiotic-impregnated spacer, a course of antibiotics, then reimplantation once infection is controlled), is generally required.[15] This is the genuinely more complex part of prosthetic joint infection management that distinguishes it from native-joint septic arthritis: the surgical decision is not simply "drain and treat," but a structured choice between salvaging and sacrificing the implant, made jointly by orthopedic surgery and infectious diseases.
Rifampin — a genuinely distinct pharmacologic point
For staphylococcal prosthetic joint infection managed with DAIR (implant retained), adding rifampin in combination with a companion oral agent (commonly a fluoroquinolone) targets bacteria within the biofilm that antibiotics alone struggle to reach — rifampin is never used as monotherapy, given how readily resistance emerges. Total duration is 3 months for a hip and 6 months for a knee prosthesis, started once surgical wound drainage has resolved.[15]
Oral therapy is increasingly appropriate — a current Canadian position
A 2025 joint statement from AMMI Canada and the Canadian Orthopaedic Association (developed with the Canadian Arthroplasty Society) supports using highly bioavailable oral antibiotics — not only as a late step-down, but from relatively early in the course — for adult bone and joint infections, including prosthetic joint infection, once: adequate source control has been achieved surgically; the causative organism is confirmed and susceptible to an appropriate oral agent; there is no other reason IV therapy is specifically required; the patient has a functioning GI tract and can be expected to adhere to a 6-12 week course; and this is done in collaboration with infectious diseases.[13] This builds directly on the landmark OVIVA trial, which established oral therapy's non-inferiority to IV therapy for bone and joint infection more broadly, and on the 2013 IDSA guideline framework above.[13]
Gonococcal arthritis and disseminated gonococcal infection
See Recognize the Condition and Choose Initial Treatment for the distinct clinical presentation and treatment regimen. A patient with recurrent or unusually severe disseminated gonococcal infection, or a family history suggestive of it, warrants consideration of an underlying terminal complement pathway deficiency — a rare but recognized predisposing condition — and referral for further workup.[6] Complete the associated STI-management bundle for every confirmed case: partner notification and empiric treatment, screening for chlamydia/syphilis/HIV, and public health reporting.[14]
Immunocompromised patients and people who inject drugs
Both presentation and laboratory findings can be blunted in an immunocompromised patient, so maintain a lower threshold to aspirate rather than a higher one, and broaden empiric gram-negative coverage (e.g., ceftazidime or piperacillin-tazobactam rather than ceftriaxone) when injection drug use, neutropenia, or another specific pseudomonas risk factor is present. In people who inject drugs, actively examine and consider imaging of atypical, easily overlooked joints — the sternoclavicular, sacroiliac, and pubic symphysis joints — since infection at these sites is both disproportionately represented in this population and more likely to be missed on a routine joint examination.
Sickle cell disease
Salmonella species are a classic and disproportionately represented cause of septic arthritis and osteomyelitis in sickle cell disease, alongside S. aureus. The genuinely important, high-stakes trap in this population is diagnostic: new bone or joint pain is easy to attribute to a routine vaso-occlusive crisis, and doing so without actively considering infection risks a missed or delayed diagnosis in a population already prone to both problems. A pain presentation that is atypical for the patient's usual crises, localizes to a single joint with objective swelling/warmth/effusion, or is accompanied by fever should prompt the same urgent aspiration-first approach used for any other patient.
Pregnancy and breastfeeding
Do not let pregnancy delay urgent aspiration or surgical drainage — the risks of untreated septic arthritis to both mother and fetus substantially outweigh the risks of appropriate treatment. Preferred empiric agents vancomycin, ceftriaxone, and cefazolin are all generally considered compatible with pregnancy and are reasonable choices for empiric or targeted therapy. Avoid where possible fluoroquinolones (e.g., levofloxacin) given animal data on cartilage effects and generally limited human safety data, and doxycycline/tetracyclines beyond about the first trimester, given the risk of fetal tooth discoloration and bone effects — if a fluoroquinolone-rifampin combination is genuinely needed for a prosthetic joint infection in pregnancy, this is a specialist infectious diseases and obstetric decision, not a routine one. Rifampin itself crosses the placenta but is used when a serious maternal infection genuinely requires it; involve infectious diseases and obstetrics jointly. Vancomycin, the penicillins/cephalosporins, and clindamycin are generally considered compatible with breastfeeding at standard doses; avoid fluoroquinolones and, in the neonatal period particularly, sulfonamide-containing agents given theoretical kernicterus risk in a jaundiced or unwell infant.
Monitoring & Follow-Up
Track clinical response daily in the acute phase: pain, swelling, range of motion, and fever trend, alongside serial CRP (which tends to trend down meaningfully faster than ESR and is generally the more useful marker for following response) — expect a clear clinical and biochemical improvement within the first several days once source control and appropriate antibiotics are both in place; a plateau or worsening picture should prompt reassessment rather than simply extending the current plan (see Treatment Failure/Next Step).
- Confirm the total antibiotic duration and route match the clinical scenario: roughly 3-4 weeks for native-joint, non-gonococcal septic arthritis in most adults (individualized — as short as 2 weeks after genuinely thorough surgical drainage in a non-immunocompromised adult with a rapid, clear response[12]); 3-4 weeks (4-6 weeks for the hip) in children[4]; more than 7 days total for gonococcal arthritis/arthritis-dermatitis syndrome, with an oral switch guided by susceptibility 24-48 hours after substantial improvement[6]; and 3 months (hip) or 6 months (knee) of rifampin-combination therapy for staphylococcal prosthetic joint infection managed with DAIR.[15]
- Confirm final culture and susceptibility results are reviewed and used to de-escalate or, if needed, broaden therapy — do not leave a patient on empiric broad-spectrum coverage by default once results are available.
- Reassess ESR/CRP before any planned reimplantation surgery in a two-stage prosthetic joint exchange, as part of confirming the infection has genuinely been controlled before proceeding.[15]
- Arrange physiotherapy and structured rehabilitation once the acute infection is controlled — restoring range of motion and strength is a real, ongoing part of recovery, not an afterthought.
- For gonococcal disease: confirm partner notification and empiric partner treatment occurred, and screen for reinfection at around 6 months post-treatment given the shared sexual-network risk.[14]
- Arrange durable orthopedic follow-up after any prosthetic joint infection, including monitoring for relapse and, in some retained-prosthesis cases, a discussion of long-term suppressive oral antibiotic therapy when the infection cannot be fully eradicated.
Common Errors to Avoid
- Treating a normal temperature or a normal serum white cell count as evidence against septic arthritis — neither reliably rules it out.[1][3]
- Waiting for imaging to be arranged and read before involving orthopedics or performing arthrocentesis when clinical suspicion is genuinely high — every hour of delay is an hour of active cartilage destruction.
- Starting antibiotics before obtaining synovial fluid and blood cultures when this is feasible, which measurably reduces the chance of identifying the causative organism.[1]
- Treating confirmed or strongly suspected septic arthritis with antibiotics alone, without arranging urgent surgical drainage — antibiotics do not substitute for source control in this condition.[1][10]
- Dismissing a negative synovial fluid culture as evidence against gonococcal arthritis — the arthritis-dermatitis pattern in particular is frequently joint-culture-negative, and blood, skin-lesion, and mucosal NAAT/culture are often more revealing.[1]
- Assuming a positive crystal analysis (gout or pseudogout) rules out coexisting infection — send Gram stain and culture on every joint aspirate regardless of crystal findings.[7]
- Applying native-joint synovial WBC thresholds to a prosthetic joint — the genuinely applicable threshold is much lower, and further depends on how recently the joint was implanted.[16]
- Giving an empiric corticosteroid injection, or assuming a "flare" diagnosis, in a joint where infection has not actually been excluded.
- In a child with hip pain, delaying orthopedic involvement while awaiting labs or imaging when clinical suspicion is high — the hip's poor accessibility and avascular-necrosis risk make this a poor place to "wait and see."
- Attributing new bone or joint pain in a patient with sickle cell disease automatically to a vaso-occlusive crisis without actively considering septic arthritis or osteomyelitis.
- Starting rifampin as monotherapy, or before surgical wound drainage has resolved, for prosthetic joint infection.
Clinical Decision Algorithm
Drug Tables
How to use this table: Doses are adult doses and require patient-specific confirmation (renal/hepatic function, weight, allergy history). Pediatric dosing is weight-based per the current product monograph unless stated. Drug pricing is intentionally omitted. Select any drug name to open its complete Pharmasist Drug Database page.
Empiric Intravenous Therapy — Native-Joint Septic Arthritis, Adults
Obtain synovial fluid and blood cultures before the first dose whenever feasible. Cover MRSA and likely gram-negative organisms pending results; broaden for pseudomonas risk (injection drug use, immunocompromise, hospital-acquired infection).
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Vancomycin (IV) | Adults: 15-20 mg/kg IV every 8-12 hours, adjusted to levels/AUC and renal function | Nephrotoxicity, infusion-related reaction ("red man syndrome"), ototoxicity | Additive nephrotoxicity with other nephrotoxic drugs (e.g., aminoglycosides) | Empiric MRSA/gram-positive coverage; requires trough or AUC monitoring and renal-function-based dosing. |
| Ceftriaxone | Adults, typical empiric dose: 1-2 g IV every 24 hours | Injection-site pain, hypersensitivity, biliary sludging | Do not co-administer with calcium-containing IV solutions | Standard empiric gram-negative partner to vancomycin; avoid in a hyperbilirubinemic neonate. |
| Ceftazidime | Adults: 2 g IV every 8 hours, adjusted for renal function | Hypersensitivity, neurotoxicity/seizures at high doses with renal impairment | Additive nephrotoxicity with other nephrotoxic drugs | Substitute for ceftriaxone when pseudomonas coverage is specifically needed; pair with a gram-positive agent. |
| Piperacillin/Tazobactam | Adults: 3.375-4.5 g IV every 6-8 hours, extended infusion preferred for serious infection | GI upset, hypersensitivity, electrolyte disturbance | Reduced efficacy of some anticoagulant monitoring assays; additive nephrotoxicity with aminoglycosides | Broad empiric alternative when wide gram-negative/anaerobic coverage is needed pending culture. |
Targeted Therapy Once an Organism and Susceptibilities Are Known
De-escalate to the narrowest effective agent once culture results are available.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Cefazolin | Adults: 2 g IV every 8 hours | Hypersensitivity, rare interstitial nephritis | Possible increased INR with warfarin | Preferred for confirmed MSSA once susceptibility is known. |
| Cloxacillin | IV: 2 g IV every 4-6 hours Oral step-down: 500 mg-1 g PO every 6 hours | GI upset, hypersensitivity reactions | May reduce efficacy of estrogen-containing contraceptives (theoretical) | Narrow, targeted therapy once MSSA is confirmed; oral step-down once appropriate. |
| Clindamycin | Adults: 600-900 mg IV every 8 hours | Clostridioides difficile-associated diarrhea, GI upset | None significant at standard doses | Beta-lactam allergy or a clindamycin-susceptible MRSA isolate; confirm with a D-test if the isolate is erythromycin-resistant. |
| Daptomycin | Adults: 6 mg/kg IV once daily (higher doses sometimes used off-label under specialist direction) | CPK elevation/myopathy — monitor weekly | Increased CPK-elevation risk with a statin; not effective for a pulmonary infection source | MRSA alternative for vancomycin intolerance, treatment failure, or a vancomycin-resistant organism. |
| Linezolid | Adults: 600 mg PO/IV every 12 hours | Thrombocytopenia/myelosuppression beyond ~2 weeks, serotonin syndrome risk, peripheral/optic neuropathy with prolonged use | Serotonin syndrome risk with SSRIs/SNRIs/MAOIs; weak MAOI activity | MRSA/VRE alternative with excellent oral bioavailability; monitor CBC weekly for multi-week courses. |
Gonococcal Arthritis / Disseminated Gonococcal Infection
Hospitalize for initial management and involve infectious diseases. Switch to an oral agent guided by susceptibility testing 24-48 hours after substantial improvement, for a total course of more than 7 days.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Ceftriaxone | Gonococcal arthritis/DGI: 1 g IM or IV every 24 hours | Injection-site pain, hypersensitivity, biliary sludging | Do not co-administer with calcium-containing IV solutions | Monotherapy backbone for gonococcal arthritis/DGI. |
| Doxycycline | Adults: 100 mg PO twice daily for 7 days | GI upset, photosensitivity, esophageal irritation | Reduced absorption with antacids/calcium/iron/dairy | Add only if chlamydial infection has not been excluded. |
Prosthetic Joint Infection — Biofilm-Directed Adjunct Therapy
For staphylococcal PJI managed with DAIR (implant retained). Start rifampin only once surgical wound drainage has resolved, and always in combination.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Rifampin | Hip prosthesis: 300-450 mg PO twice daily, combined with a companion oral agent, for a total of 3 months Knee prosthesis: 300-450 mg PO twice daily, combined with a companion oral agent, for a total of 6 months | Hepatotoxicity, orange discoloration of urine/secretions | Potent CYP450 inducer — extensive interactions (e.g., reduces efficacy of warfarin, many antiretrovirals, hormonal contraceptives) | Never used as monotherapy given how readily resistance emerges. |
| Levofloxacin | Adults: 500-750 mg PO/IV once daily | Tendinopathy risk, QTc prolongation, CNS effects | Reduced absorption with antacids/metal cations/dairy; avoid with other QTc-prolonging drugs | Common rifampin companion agent once susceptibility is confirmed; also used for gram-negative step-down. |
Pediatric Empiric Therapy — Children Under About 2-3 Years
Covers the two dominant pediatric pathogens (MSSA and Kingella kingae); broaden for MRSA risk if indicated. Neonates: cefotaxime is preferred over ceftriaxone when hyperbilirubinemia is present, given ceftriaxone's bilirubin-displacement risk.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Cefazolin | Pediatric: 100-150 mg/kg/day IV divided every 6-8 hours | Hypersensitivity, rare interstitial nephritis | Possible increased INR with warfarin | The empiric agent recommended in current Canadian pediatric guidance. |
Crystal Arthropathy Flare — Once Septic Arthritis Is Addressed or Confidently Excluded
Never given empirically for a presumed inflammatory monoarthritis before septic arthritis has been excluded — corticosteroids and, to a lesser extent, NSAIDs can mask an unrecognized infection.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Colchicine | Adults: 0.6 mg PO once or twice daily | GI upset (diarrhea, nausea), myelosuppression/myopathy risk in renal impairment or with interacting drugs | Numerous significant interactions, including strong CYP3A4/P-glycoprotein inhibitors | Dose-reduce or avoid in significant renal/hepatic impairment. |
| Naproxen | Adults: 250-500 mg PO twice daily with food | GI upset/bleeding, renal impairment, cardiovascular risk | Increased bleeding risk with anticoagulants/antiplatelets | Analgesia/anti-inflammatory once infection is controlled, or for a confirmed crystal flare. |
| Prednisone | Adults: 30-40 mg PO once daily, tapered over 10-14 days | Hyperglycemia, mood changes, insomnia | Increased hyperglycemia risk in diabetes; numerous drug interactions with chronic use | Alternative when NSAIDs/colchicine are contraindicated — only once infection is confidently excluded or controlled. |
References
- Septic Arthritis — StatPearls Publishing (Momodu II, Savaliya V). StatPearls, last updated July 3, 2023
- Clinical management of septic arthritis — Current Rheumatology Reports (Sharff KA, Richards EP, Townes JM). Curr Rheumatol Rep 2013;15(6):332
- Does This Adult Patient Have Septic Arthritis? — JAMA (Margaretten ME, Kohlwes J, Moore D, Bent S). JAMA 2007;297(13):1478-1488
- Diagnosis and management of acute osteoarticular infections in children — Paediatrics & Child Health, Canadian Paediatric Society, Infectious Diseases and Immunization Committee (Le Saux N). Paediatr Child Health 2018;23(5):336-343, reaffirmed January 2024
- Gonorrhea guide: Risk factors and clinical manifestations — Canadian Guidelines on Sexually Transmitted Infections, Public Health Agency of Canada. PHAC Canadian Guidelines on Sexually Transmitted Infections
- Sexually Transmitted Infections Treatment Guidelines, 2021 — MMWR Recommendations and Reports, Centers for Disease Control and Prevention (Workowski KA, Bachmann LH, Chan PA, et al.). MMWR Recomm Rep 2021;70(4):1-187
- Coexisting polyarticular septic arthritis, gout and pseudogout — BMJ Case Reports (Colaco C, Dotel R). BMJ Case Rep 2018;2018:bcr2018226810
- Differentiating between septic arthritis and transient synovitis of the hip in children: an evidence-based clinical prediction algorithm — Journal of Bone and Joint Surgery, American Volume (Kocher MS, Zurakowski D, Kasser JR). J Bone Joint Surg Am 1999;81(12):1662-1670
- Validation of a clinical prediction rule for the differentiation between septic arthritis and transient synovitis of the hip in children — Journal of Bone and Joint Surgery, American Volume (Kocher MS, Mandiga R, Zurakowski D, Barnewolt C, Kasser JR). J Bone Joint Surg Am 2004;86(8):1629-1635
- Bacterial septic arthritis in adults — The Lancet (Mathews CJ, Weston VC, Jones A, Field M, Coakley G). Lancet 2010;375(9717):846-855
- Treatment options for neonatal infections in the post-cefotaxime era — Expert Review of Anti-infective Therapy (Hammerschlag MR). Expert Rev Anti Infect Ther 2022;20(10):1253-1259
- Two weeks versus four weeks of antibiotic therapy after surgical drainage for native joint bacterial arthritis: a prospective, randomised, non-inferiority trial — Annals of the Rheumatic Diseases (Gjika E, Beaulieu JY, Vakalopoulos K, Gauthier M, Bouvet C, Gonzalez A, Morello V, Steiger C, Hirsiger S, Lipsky BA, Uckay I). Ann Rheum Dis 2019;78(8):1114-1121
- Joint Statement: Oral Treatment for Bone and Joint (Including Prosthetic Joint) Infections — AMMI Canada & Canadian Orthopaedic Association, developed with the Canadian Arthroplasty Society. AMMI Canada/COA Joint Statement, approved January 16, 2025
- Gonorrhea guide: Treatment and follow-up — Canadian Guidelines on Sexually Transmitted Infections, Public Health Agency of Canada. PHAC Canadian Guidelines on Sexually Transmitted Infections
- Diagnosis and Management of Prosthetic Joint Infection: Clinical Practice Guidelines by the Infectious Diseases Society of America — Clinical Infectious Diseases, Infectious Diseases Society of America (Osmon DR, Berbari EF, Berendt AR, et al.). Clin Infect Dis 2013;56(1):e1-e25
- The 2018 Definition of Periprosthetic Hip and Knee Infection: An Evidence-Based and Validated Criteria — Journal of Arthroplasty (Parvizi J, Tan TL, Goswami K, Higuera C, Della Valle C, Chen AF, Shohat N). J Arthroplasty 2018;33(5):1309-1314
Professional reference only. Apply clinical judgment and verify patient-specific decisions against current authoritative guidance and product information.